Clinical Intergroup – Description
The Clinical Intergroup working party was founded in 1996 and is currently involving following national study groups (representatives in brackets):
- CLSG (M. Trneny, Prag/Czech Republic)
- EORTC Lymphoma Group (H. Kluin-Nelemans, Groningen/Netherlands)
- GELA (O. Hermine, Paris/France)
- GLSG (W. Hiddemann/Germany)
- GOELAMS (R. Gressin, Grenoble/France)
- HOVON (M. van t’Veer, Rotterdam/Netherlands)
- Israelian Study group (O. Shpilberg, Petah-Tiqva/Israel)
- Nordic Lymphoma Group (C. Geissler, Copenhagen/Denmark)
- OSHO (M. Herold, Erfurt/Germany)
- PLRG (J. Walewski, Warzawa/Poland)
- SAKK (N. Ketterer, Lausanne)
Due to the delayed international acceptance of the subentity of mantle cell lymphoma, in a first retrospective survey, this group collected the clinical data of 592 patients with MCL. This retrospective analysis confirmed the dismal prognosis of MCL with a median survival of 3 years and virtually not long term survivors. Even more interesting, conventional chemotherapy was not able to improve the biological course of the disease.
In the subsequent first generation of therapeutic study, important clinical results could be achieved by the clinical cooperation group. In close collaboration with the GLSG, analysis of more than 200 patients recruited within this trial confirmed that a combined immuno-chemotherapy results in a significantly improved response and survival rates in relapsed mantle cell lymphomas.
In the first European trial on high dose therapy in malignant lymphoma, the European MCL Intergroup working party could prove that an intensive consolidation with autologous stem cell transplantation results in an extended progression-free survival based on the evaluation of more than 200 patients treated within the study.
Currently, following studies have been initiated:
- R-CHOP followed by myeloablative consolidation vs. R-CHOP/R-DHAP followed by high dose Ara-C therapy (patients < 65 years, randomized phase III)
- R-CHOP vs. R-FC followed by Rituximab maintenance vs. observation (patients > 65 years, randomized phase III)
- FCM+/-Rituximab followed by observation vs. Rituximab maintenance (randomized phase III in collaboration with the GLSG)
- Radioimmunotherapy with a Yttrium-labeled anti CD20 antibody (phase II)
- Allogeneic transplantation with dose reduced conditioning (phase II)
Built on the established infrastructure of the Clinical MCL Intergroup Working
Party this workpackage aims at the evaluation of promising, new treatment
options in MCL to improve the clinical course of this aggressive lymphoma
in prospective, randomized studies. Previous trial generations of the European
collaboration of clinicians has, for the first time, confirmed the superiority
of innovative treatment options. In the current study generation, further
optimized application of myeloablative radiochemotherapy as well as combined
immuno-chemotherapy should be achieved.
This setting of a controlled study is a crucial point for the evaluation of new predictive and prognostic markers.